Rikke Nørregaard

Rikke Nørregaard says: “Chronic kidney disease (CKD) is a leading cause of mortality and the disease is currently affecting about 10% of the population. Current treatment strategies are ineffective at preventing disease progression. Our project will establish a targeted stem cell-based therapy to reduce renal fibrosis in CKD. We will genetically modify stem cells to enhance production and secretion of specific tissue-repair factors. The hypothesis is that gene-edited stem cells secreting tissue-repair factors can be utilized as a therapeutic modality to inhibit progression of renal fibrosis. Combining biochemical and integrative physiology which takes advantage of a broad variety of established models, including cell systems, animal models and human samples, we will study stem cell-based therapy for the treatment of renal fibrosis in CKD.”